17,261 trials
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Participants With and Without Hypersensitivity Reaction — 9; 6; 49; 50 Participants
Sleep · Insomnia
Primary: Hemodynamic Stability (Phase I) — 0; 0; 0; 0 Participants
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Number of Participants Reported With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs) — 6; 0; 5 Participants
Breast Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5 months
H. Pylori Infection
Primary: Overall Percent Agreement — 98.40; 99.20 percentage of pos. agreement
Cholangiocarcinoma · Stage III Gallbladder Cancer AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7
Primary: 16-Week Progression-free Survival (PFS) Rate — 32.0 percentage of patients
AIDS · HIV Infections
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 2; 0; 2; 49 Participants
Advanced Cancers · Sarcoma
Primary: Recurrence Free Survival — 13.99 months
Metastatic Pancreatic Cancer
Primary: Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. — 0; 3 Participants
Hypertension · Hyperlipidemia
Primary: Systolic Blood Pressure — 138; 131 mm Hg
Lung Cancer · Radiation Pneumonitis
Primary: Number of Participants With Radiation Pneumonitis — 8; 10 participants — p=0.05
Liver Cancer
Primary: Time to Progression (TTP) in Patients Treated With TACE and Y90 — 26; 6.8 Months — p=0.007
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Patients With Objective Response (OR) in Part A According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 — 0.0 Percentage of participants
Recurrent Adult Hodgkin Lymphoma · Recurrent Childhood Hodgkin Lymphoma · Refractory Childhood Hodgkin Lymphoma
Primary: Maximum Tolerated Dose (MTD) for Brentuximab Vedotin — 1.8 mg/kg
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) in Part 2